A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Keyphrases

• Non-alcoholic Fatty Liver Disease (NAFLD) 100%
• Liver Fat Content 100%
• Active Comparator 100%
• Semaglutide 80%
• Glucagon-like 50%
• A1 Receptor 30%
• Receptor Agonist 30%
• Nonalcoholic Steatohepatitis 30%
• Glucagon Receptor 30%
• Co-agonist 20%
• Weight Loss 20%
• Type 2 Diabetes Mellitus (T2DM) 20%
• Relative Reduction 20%
• Least Mean Square 20%
• Clinical Trials 10%
• Disease Treatment 10%
• Effective Treatment 10%
• Magnetic Resonance Imaging 10%
• Agonism 10%
• Number of Trials 10%
• Treatment Group 10%
• Liver 10%
• High Incidence 10%
• Lipogenesis 10%
• Adverse Events 10%
• Drug Adverse Events 10%
• Hepatic Inflammation 10%
• Fatty Acid Oxidation 10%
• Once-weekly 10%
• Percentage Reduction 10%
• Gastrointestinal Side Effects 10%
• Adverse Drug 10%
• Target Dose 10%
• Efficacy Endpoint 10%
• EudraCT 10%
• Concurrent Diagnoses 10%
• Proton Density Fat Fraction 10%

Medicine and Dentistry

• Nonalcoholic Fatty Liver 100%
• Fat Content 100%
• Efinopegdutide 100%
• Semaglutide 80%
• Adverse Event 30%
• Glucagon Receptor 30%
• Glucagon-Like Peptide-1 Agonist 30%
• Maturity Onset Diabetes of the Young 20%
• Least Square Analysis 20%
• Glucagon Like Peptide 1 20%
• Body Mass Index 10%
• Magnetic Resonance Imaging 10%
• Combination Therapy 10%
• Clinical Trial 10%
• Body Weight 10%
• Fatty Acid Oxidation 10%
• Lipogenesis 10%
• Neutron Capture Therapy 10%
• Treatment Group 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Fatty Liver 100%
• Nonalcoholic Fatty Liver 100%
• Efinopegdutide 100%
• Semaglutide 80%
• Adverse Event 30%
• Glucagon Like Peptide 1 Receptor Agonist 30%
• Glucagon Receptor 30%
• Glucagon-Like Peptide-1 20%
• Non Insulin Dependent Diabetes Mellitus 20%
• Clinical Trial 10%
• Inflammation 10%
• Combination Therapy 10%
• Fatty Acid 10%
• Treatment Group 10%